Organization and Basis of Presentation	6 Months Ended
Sep. 30, 2026
Organization and Basis of Presentation
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Description of the Company FairWind Energy, Inc. (the “Company”) was incorporated on April 18, 2013 under the laws of the State of Nevada. Effective June 17, 2019, the Company changed its name to Agentix Corp. In March 2022, the Company changed its fiscal year end from August to March. The Company is a clinical-stage biotechnology company developing therapeutic agents for the treatment of metabolic disease like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Going Concern The Company’s unaudited consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the unaudited consolidated financial statements, the Company had an accumulated deficit of $7,215,863 as of September 30, 2026, a net loss of $208,699 and net cash used in operating activities of $29,894 for the six months ended September 30, 2026, and negative working capital of $3,807,025 as of September 30, 2026. Cash on hand as of September 30, 2026 was $1,312. The Company is attempting to commence operations and generate sufficient revenue; however, the Company’s cash position is not sufficient to support its daily operations, and it will need further funding. The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds. The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Principles of Consolidation The unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, GSL Healthcare, Inc., AB Merger LLC, Agentix Australia Pty Ltd, and Applied Biopharma, all of which are 100% owned by the Company. Intercompany transactions and balances have been eliminated in consolidation. Except for Agentix Australia Pty Ltd, the Company’s subsidiaries had no material operations or activity during the periods presented.

Organization and Basis of Presentation

6 Months Ended

Sep. 30, 2026

Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

Description of the Company

FairWind Energy, Inc. (the “Company”) was incorporated on April 18, 2013 under the laws of the State of Nevada. Effective June 17, 2019, the Company changed its name to Agentix Corp. In March 2022, the Company changed its fiscal year end from August to March.

The Company is a clinical-stage biotechnology company developing therapeutic agents for the treatment of metabolic disease like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Going Concern

The Company’s unaudited consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

As reflected in the unaudited consolidated financial statements, the Company had an accumulated deficit of $7,215,863 as of September 30, 2026, a net loss of $208,699 and net cash used in operating activities of $29,894 for the six months ended September 30, 2026, and negative working capital of $3,807,025 as of September 30, 2026. Cash on hand as of September 30, 2026 was $1,312.

The Company is attempting to commence operations and generate sufficient revenue; however, the Company’s cash position is not sufficient to support its daily operations, and it will need further funding. The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds.

The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Principles of Consolidation

The unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, GSL Healthcare, Inc., AB Merger LLC, Agentix Australia Pty Ltd, and Applied Biopharma, all of which are 100% owned by the Company. Intercompany transactions and balances have been eliminated in consolidation. Except for Agentix Australia Pty Ltd, the Company’s subsidiaries had no material operations or activity during the periods presented.